Form D · Biotechnology

Allon Therapeutics Inc

Vancouver, A1 · CIK 0001306079

Offering snapshot reported May 17, 2012 · SEC filing

Reported sold: $1.63M
Investors reported: 2
Minimum accepted: $0
First sale: May 1, 2012

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 17, 2012	Initial	$1,626,182	No comparison	2	SEC filing
Jun 7, 2007	Paper	Not reported	No comparison	Not reported	SEC filing
Dec 5, 2006	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Equity, Option to acquire, Security to be acquired, Other
Exemptions: 06
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-178424

13a=price of units(2,000,000 @ C$0.25), plus price of sub receipts convertible to units(C$1,100,000) for no additional consideration, plus exercise price of underlying warrants(3,200,000 @ C$0.40), converted to US$. No guarantee warrants will be exercised

SUBSCRIPTION RECEIPTS

Source: Form D, filed May 17, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Michael Aldridge	Director
Martin Barkin	Director
Matthew J Carlyle	Executive
Michael Gold	Executive
Illana Gozes	Director
Frank A Holler	Director
Gordon C Mc Cauley	Director, Executive
James J Miller	Director
Bruce H Morimoto	Executive
Anthony G Phillips	Director
Alistair Stewart	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

Suite 506, 1168 Hamilton Street
Vancouver, A1, V6B 2S2